Welcome to our dedicated page for Inmed Pharmaceuticals news (Ticker: INM), a resource for investors and traders seeking the latest updates and insights on Inmed Pharmaceuticals stock.
InMed Pharmaceuticals Inc. (NASDAQ: INM) is a pharmaceutical drug development company that regularly issues news and updates about its proprietary small molecule programs and related corporate activities. The company focuses on drug candidates targeting the CB1/CB2 receptors in three main therapeutic areas: Alzheimer’s disease, ocular conditions and dermatological indications, and it also reports on the commercial operations of its rare cannabinoid subsidiary BayMedica.
News about InMed often covers progress in its lead Alzheimer’s program INM-901, including preclinical data, pharmacokinetic studies in animal models and scientific presentations at major conferences such as the Alzheimer’s Association International Conference (AAIC). Releases describe how INM-901 is being evaluated across multiple biological pathways associated with Alzheimer’s disease and summarize findings from long-term studies in established disease models.
Investors and followers of INM can also find updates on INM-089, a proprietary small molecule drug candidate under investigation for dry age-related macular degeneration, including preclinical study results and formulation work for intravitreal delivery. In addition, InMed provides business updates on BayMedica, including sales performance, legislative developments affecting rare, non-intoxicating cannabinoids and the subsidiary’s evaluation of alternative supply chain options to maintain regulatory compliance.
Corporate and capital markets developments are another frequent theme in InMed’s news flow. The company announces private placements, preferred investment option amendments, participation in investor conferences, and changes to its board of directors, as well as the outcomes of its annual general and special meetings of shareholders. For readers tracking INM news, this page offers a centralized view of scientific, commercial, financial and governance announcements directly tied to the company’s disclosed activities.
InMed Pharmaceuticals (NASDAQ: INM) reported its fiscal year 2025 financial results and provided updates on its pharmaceutical pipeline. The company recorded $4.9M in revenue (8% YoY increase) and a net loss of $8.2M. Cash position stands at $11.1M, sufficient to fund operations into Q4 2026.
Key developments include advancement of INM-901 for Alzheimer's disease, demonstrating significant reductions in neuroinflammation and improved cognitive outcomes in preclinical studies. The company also progressed with INM-089 for dry age-related macular degeneration, showing promising neuroprotective results.
Research and development expenses were $2.9M, down from $3.2M in 2024, while general and administrative expenses increased to $6.6M from $5.8M in the previous year.
[ "Cash position of $11.1M provides runway into Q4 2026", "BayMedica revenue increased 8% YoY to $4.9M", "INM-901 showed statistically significant reductions in neuroinflammation markers", "Successful oral administration of INM-901 achieving therapeutic brain levels", "R&D expenses decreased from $3.2M to $2.9M year-over-year" ]InMed Pharmaceuticals (NASDAQ: INM) announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference in New York. The company's Chief Operating Officer, Michael Woudenberg, will deliver a corporate presentation highlighting updates on InMed's pipeline, including recent data from their leading pharmaceutical program INM-901 for Alzheimer's treatment.
The presentation will be available via webcast for 90 days, and InMed's management team will conduct one-on-one meetings with investors during the conference. The recent data from INM-901 was previously presented at the Alzheimer's Association International Conference (AAIC) 2025.
InMed Pharmaceuticals (NASDAQ: INM) announced the presentation of new preclinical data for its INM-901 drug candidate at the upcoming Alzheimer's Association International Conference (AAIC) 2025 in Toronto. The study evaluated INM-901's long-term treatment effects in a 5xFAD mouse model of advanced Alzheimer's disease.
The research demonstrated that INM-901 showed multiple positive effects, including: reduction in inflammatory biomarkers, decreased amyloid-beta immunoreactivity, partial restoration of MAP2 protein, and improvements in cognitive function. The drug candidate exhibited dose-dependent therapeutic effects in neuroinflammation and showed promise in restoring behavioral and sensory responses to normal levels.
The data will be presented in a scientific poster titled "Therapeutic Potential of INM-901 in Mitigating Alzheimer's Disease Pathology: Insights from a Long-term 5xFAD Mouse Model Study" at AAIC 2025, scheduled for July 27-31.
InMed Pharmaceuticals (NASDAQ: INM) has closed a private placement offering, raising $5 million through the sale of 1,952,363 common shares (or pre-funded warrants) at $2.561 per share. The offering includes short-term preferred investment options exercisable at $2.436 per share, which could generate an additional $4.75 million if fully exercised.
The company plans to use the proceeds for pipeline development of pharmaceutical drug candidates, support commercial sales through BayMedica LLC subsidiary, and general working capital. Additionally, InMed amended existing preferred investment options from October 2023, reducing the exercise price from $16.60 to $2.436 per share.
InMed Pharmaceuticals (NASDAQ: INM) has announced a $5 million private placement with a single institutional investor. The company will issue 1,952,363 common shares (or pre-funded warrants) and short-term preferred investment options at $2.561 per share.
The offering includes short-term preferred investment options exercisable at $2.436 per share, expiring 18 months after the Resale Registration Statement's effective date. If fully exercised, these options could generate additional proceeds of $4.75 million. The company will use funds for pipeline development, supporting BayMedica LLC's commercial sales, and working capital.
Additionally, InMed will amend existing preferred investment options from October 2023, reducing the exercise price from $16.60 to $2.436 per share.
InMed Pharmaceuticals (NASDAQ: INM) has announced promising preclinical results for INM-901, their therapeutic candidate for Alzheimer's disease. In an ex vivo study, INM-901 demonstrated significant reduction of neuroinflammation in animal brain tissue.
The study revealed that INM-901 significantly reduced levels of key inflammatory markers, including NLRP3, IL-6, IL-1β, KC/Gro, and IL-2. Notably, these anti-inflammatory effects were achieved independently of amyloid beta or tau pathology, suggesting potential applications in various dementia-related diseases.
INM-901's key characteristics include oral administration capability, neuroprotective effects through CB1/CB2 receptor interaction, and demonstrated improvements in cognitive function and memory in preclinical studies. The company plans to advance INM-901 through additional preclinical studies, followed by IND-enabling studies.
InMed Pharmaceuticals (NASDAQ: INM) reported Q2 FY2025 financial results, posting a net loss of $2.6M compared to $1.5M in the same period last year. The company's BayMedica commercial unit generated revenues of $1.1M, a 10% decrease from the previous year, but achieved a net income of $0.23M, representing a 189% improvement.
Key developments include positive results from INM-901's preclinical Alzheimer's disease study, showing reduction in neuroinflammatory markers, and the selection of an intravitreal formulation for INM-089 in dry AMD treatment. The company's cash position stood at $3.5M as of December 31, 2024, with an additional $2.9M raised in January 2025, expected to fund operations through Q2 2025.
Operating expenses increased with R&D costs rising to $1M from $0.6M, and G&A expenses reaching $1.6M compared to $1.4M in the previous year.
InMed Pharmaceuticals (NASDAQ: INM) has announced the selection of an intravitreal (IVT) formulation for INM-089 as a drug candidate for treating dry age-related macular degeneration (AMD). The company has achieved successful delivery of the formulation at doses up to 10 times the projected therapeutic level, demonstrating a favorable pharmacokinetic profile and significant safety margin.
The company has completed dose-ranging in vivo studies, which will guide the selection of appropriate doses for pivotal preclinical toxicology studies. The INM-089 IVT formulation will proceed to GLP-enabling studies and subsequent clinical development stages. InMed chose intravitreal injection as the delivery method, noting it's the established standard of care among retinal specialists, particularly given the challenges of delivering lipophilic drugs through topical formulations like eye drops.